Compugen Ltd. (NASDAQ:CGEN – Get Free Report) has been assigned an average rating of “Buy” from the five ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $5.00.
A number of brokerages have recently issued reports on CGEN. Weiss Ratings upgraded shares of Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. HC Wainwright reissued a “buy” rating on shares of Compugen in a report on Tuesday, August 4th.
Get Our Latest Stock Report on Compugen
Compugen Price Performance
Compugen (NASDAQ:CGEN – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The business had revenue of $2.60 million for the quarter, compared to the consensus estimate of $1.28 million. Compugen had a net margin of 47.56% and a return on equity of 42.57%. During the same quarter in the prior year, the company earned ($0.08) EPS. As a group, sell-side analysts anticipate that Compugen will post -0.28 EPS for the current year.
Institutional Investors Weigh In On Compugen
Several hedge funds and other institutional investors have recently made changes to their positions in CGEN. Renaissance Technologies LLC raised its position in shares of Compugen by 12.1% during the first quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock worth $3,478,000 after acquiring an additional 176,088 shares during the last quarter. WINTON GROUP Ltd increased its position in Compugen by 26.0% in the second quarter. WINTON GROUP Ltd now owns 197,110 shares of the biotechnology company’s stock worth $422,000 after purchasing an additional 40,614 shares during the period. Platform Technology Partners increased its position in Compugen by 10.0% in the first quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 5,000 shares during the period. Squarepoint Ops LLC bought a new stake in Compugen during the 2nd quarter worth about $110,000. Finally, Glenmede Trust Co. NA raised its holdings in Compugen by 187.5% during the 1st quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 22,500 shares during the last quarter. 12.22% of the stock is owned by institutional investors and hedge funds.
Compugen Company Profile
Compugen Ltd. is an Israeli clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for cancer and other serious diseases. The company uses computational biology, data analysis and related technologies to identify novel drug targets and develop antibody-based medicines, with an emphasis on immuno-oncology.
Compugen’s pipeline includes investigational immune checkpoint therapies designed to reactivate anti-tumor immune responses. Its leading programs have included COM701, an antibody targeting PVRIG, and COM902, an antibody targeting TIGIT.
Featured Stories
- Five stocks we like better than Compugen
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
